New Jersey District Court Rules For Ranbaxy In Glaxo Patent Suit
The Indian generic drug maker has been selling its antibiotic, cefuroxime axetil, since 2001, when a federal appeals court vacated a preliminary injunction GlaxoSmithKline had won from a lower court in October 2000, according to Ranbaxy.
Ceftin had global sales of $404 million in 2003, GlaxoSmithKline said.
Ranbaxy reported U.S. cefuroxime axetil sales of $134.8 million in 2003....
To view the full article, register now.